自身免疫性肝炎的研究现状与展望

王绮夏; 马雄

doi:10.3969/j.issn.1001-5256.2020.04.001

自身免疫性肝炎的研究现状与展望

DOI: 10.3969/j.issn.1001-5256.2020.04.001

王绮夏,
马雄

上海交通大学医学院附属仁济医院消化内科上海市消化疾病研究所

基金项目:

国家自然科学基金项目(81770564,81790634,81620108002,81771732,81830016)；上海市卫生计生系统优秀青年医学人才培养计划(2017YQ037)；上海市青年科技启明星计划(18QA1402700)；

详细信息

中图分类号: R575.1
计量
- 文章访问数: 1516
- HTML全文浏览量: 24
- PDF下载量: 512
- 被引次数: 0
出版历程
- 出版日期: 2020-04-20

Current status and perspectives of autoimmune hepatitis

Department of Gastroenterology, Shanghai Institute of Digestive Diseases, Renji Hospital, Shanghai Jiaotong University School of Medicine

Research funding:

摘要

摘要: 自身免疫性肝炎(AIH)是遗传易感个体在环境等因素诱导下出现的自身免疫性肝病,以血清自身抗体阳性、高免疫球蛋白G血症、转氨酶水平升高和界面性肝炎为主要特征。AIH发病机制尚未完全阐明,临床诊治过程中亦有较高异质性,患者个体化的精准医学诊疗显得尤为重要。为此,结合近年来本领域重要研究进展和难点问题进行述评。
- 肝炎,自身免疫性 /
- 治疗学 /
- 预后
Abstract: Autoimmune hepatitis( AIH) is an autoimmune liver disease induced by environmental factors in individuals with genetic susceptibility,with the main features of positive serum autoantibody,hypergammaglobulinemia,elevated transaminases,and interface hepatitis.The pathogenesis of AIH remains unknown,high heterogeneity is observed in clinical diagnosis and treatment,and thus it is of great importance to establish individualized precise diagnosis and treatment. Therefore,this article reviews the research advances and difficult issues in this field.
- hepatitis,autoimmune /
- therapeutics /
- prognosis

HTML全文

参考文献(22)

[1] MIELI-VERGANI G,VERGANI D,CZAJA AJ,et al. Autoimmune hepatitis[J]. Nat Rev Dis Primers,2018,4:18017.

[2] ALVAREZ F,BERG PA,BIANCHI FB,et al. International Autoimmune Hepatitis Group Report:Review of criteria for diagnosis of autoimmune hepatitis[J]. J Hepatol,1999,31(5):929-938.

[3] HENNES EM,ZENIYA M,CZAJA AJ,et al. Simplified criteria for the diagnosis of autoimmune hepatitis[J]. Hepatology,2008,48(1):169-176.

[4] WANG Q,YANG F,MIAO Q,et al. The clinical phenotypes of autoimmune hepatitis:A comprehensive review[J]. J Autoimmun,2016,66:98-107.

[5] WANG QX,YAN L,MA X. Autoimmune hepatitis in the AsiaPacific area[J]. J Clin Transl Hepatol,2018,6(1):48-56.

[6] MACK CL,ADAMS D,ASSIS DN,et al. Diagnosis and management of autoimmune hepatitis in adults and children:2019practice guidance and guidelines from the American Association for the Study of Liver Diseases[J]. Hepatology,2019.[Epub ahead of print]

[7] TANG R,WEI Y,LI Y,et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J]. Gut,2018,67(3):534-541.

[8] MANFREDO VIEIRA S,HILTENSPERGER M,KUMAR V,et al.Translocation of a gut pathobiont drives autoimmunity in mice and humans[J]. Science,2018,359(6380):1156-1161.

[9] WEI Y,LI Y,YAN L,et al. Alterations of gut microbiome in autoimmune hepatitis[J]. Gut,2020,69(3):569-577.

[10] VIGNALI DA,KUCHROO VK. IL-12 family cytokines:Immunological playmakers[J]. Nat Immunol,2012,13(8):722-728.

[11] LIAN M,ZHANG J,ZHAO L,et al. Interleukin-35 regulates immune microenvironment of autoimmune hepatitis through inducing the expansion of myeloid-derived suppressor cells[J]. Front Immunol,2019,10:2577.

[12] RAHIM MN,LIBERAL R,MIQUEL R,et al. Acute severe autoimmune hepatitis:Corticosteroids or liver transplantation?[J]. Liver Transpl,2019,25(6):946-959.

[13] ANAND L,CHOUDHURY A,BIHARI C,et al. Flare of autoimmune hepatitis causing acute on chronic liver failure:Diagnosis and response to corticosteroid therapy[J]. Hepatology,2019,70(2):587-596.

[14] SARIN SK,CHOUDHURY A,SHARMA MK,et al. Correction to:Acute-on-chronic liver failure:Consensus recommendations of the Asian Pacific Association for the Study of the Liver(APASL):An update[J]. Hepatol Int,2019,13(6):826-828.

[15] PEISELER M,LIEBSCHER T,SEBODE M,et al. Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol,2018,16(2):260-267. e1.

[16] van den BRAND FF,van der VEEN KS,LISSENBERG-WITTE BI,et al. Adverse events related to low dose corticosteroids in autoimmune hepatitis[J]. Aliment Pharmacol Ther,2019,50(10):1120-1126.

[17] SCHMIDT T,SCHMIDT C,STRAHL A,et al. A system to determine risk of osteoporosis in patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol,2020,18(1):226-233. e3.

[18] PAPE S,GEVERS T,VROLIJK JM,et al. Rapid response to treatment of autoimmune hepatitis associated with remission at6 and 12 months[J]. Clin Gastroenterol Hepatol,2019.[Epub ahead of print]

[19] WANG Q,QIU D,MA X. Early normalisation of aminotransferase predicts complete biochemical remission in autoimmune hepatitis patients[J]. Aliment Pharmacol Ther,2011,34(1):107-109.

[20] TANSEL A,KATZ LH,EL-SERAG HB,et al. Incidence and determinants of hepatocellular carcinoma in autoimmune hepatitis:A systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol,2017,15(8):1207-1217. e4.

[21] van den BRAND FF,van der VEEN KS,de BOER YS,et al.Increased mortality among patients with vs without cirrhosis and autoimmune hepatitis[J]. Clin Gastroenterol Hepatol,2019,17(5):940-947. e2.

[22] CHEN RL,WANG QX,MA X. Precision medicine for autoimmune hepatitis[J]. J Dig Dis,2019,20(7):331-337.

施引文献

资源附件(0)

访问统计